文献速递乳腺技术与安全MR

基于治疗前灌注MRI的肿瘤内异质性预测三阴性乳腺癌对新辅助化疗免疫治疗的病理学反应

Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.
PubMed 文献 · Radiology · 2024-01-01

这项前瞻性研究纳入两个中心自2021年8月至2023年7月接受新辅助化疗免疫治疗的早期三阴性乳腺癌女性,利用治疗前动态对比增强MRI的药代动力学参数提取影像组学特征构建评分,该评分预测病理学完全缓解的AUC为0.80(95%CI:0.70,0.89),联合分级与Ki-67的列线图在外部测试集AUC为0.86(95%CI:0.78,0.94)。

要点

  • 治疗前DCE-MRI药代动力学参数影像组学评分预测pCR的AUC为0.80(95%CI:0.70,0.89)。
  • 联合影像组学评分、分级和Ki-67的列线图在外部测试集AUC为0.86(95%CI:0.78,0.94)。
  • 较高影像组学评分(>0.25)与肿瘤大小、廓清强化、雄激素受体及PD-L1表达存在关联。

核心结论

  • 基于治疗前动态对比增强MRI药代动力学参数构建的影像组学评分对接受新辅助化疗免疫治疗的三阴性乳腺癌患者的病理学完全缓解表现出良好预测效能,可能有助于增强临床决策。

研究设计与样本

  • 前瞻性研究,训练集为中心1的112例女性参与者(平均年龄52岁±11[SD]),外部测试集为中心2的83例女性参与者(平均年龄47岁±11),纳入2021年8月至2023年7月接受新辅助化疗免疫治疗的早期三阴性乳腺癌女性,使用多厂商扫描仪获取的治疗前动态对比增强MRI,采用Tofts模型分割肿瘤并分析药代动力学参数。

诊断标准与关键数值

  • 影像组学评分预测病理学完全缓解的AUC为0.80(95%CI:0.70,0.89);纳入影像组学评分、分级和Ki-67的列线图在测试集AUC为0.86(95%CI:0.78,0.94);较高影像组学评分(>0.25)与肿瘤大小(P < .001)、廓清强化(P = .01)、雄激素受体表达(P = .009)和程序性死亡配体1表达(P = .01)存在关联。

临床应用与阅片要点

  • 作者认为基于治疗前动态对比增强MRI药代动力学参数的影像组学评分可能有助于增强临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Neoadjuvant chemoimmunotherapy (NACI) has significantly increased the rate of pathologic complete response (pCR) in patients with early-stage triple-negative breast cancer (TNBC), although predictors of response to this regimen have not been identified. Purpose To investigate pretreatment perfusion MRI-based radiomics as a predictive marker for pCR in patients with TNBC undergoing NACI. Materials and Methods This prospective study enrolled women with early-stage TNBC who underwent NACI at two different centers from August 2021 to July 2023. Pretreatment dynamic contrast-enhanced MRI scans obtained using scanners from multiple vendors were analyzed using the Tofts model to segment tumors and analyze pharmacokinetic parameters. Radiomics features were extracted from the rate constant for contrast agent plasma-to-interstitial transfer (or Ktrans), volume fraction of extravascular and extracellular space (Ve), and maximum contrast agent uptake rate (Slopemax) maps and analyzed using unsupervised correlation and least absolute shrinkage and selector operator, or LASSO, to develop a radiomics score. Score effectiveness was assessed using the area under the receiver operating characteristic curve (AUC), and multivariable logistic regression was used to develop a multimodal nomogram for enhanced prediction. The discrimination, calibration, and clinical utility of the nomogram were evaluated in an external test set. Results The training set included 112 female participants from center 1 (mean age, 52 years ± 11 [SD]), and the external test set included 83 female participants from center 2 (mean age, 47 years ± 11). The radiomics score demonstrated an AUC of 0.80 (95% CI: 0.70, 0.89) for predicting pCR. A nomogram incorporating the radiomics score, grade, and Ki-67 yielded an AUC of 0.86 (95% CI: 0.78, 0.94) in the test set. Associations were found between higher radiomics score (>0.25) and tumor size (P < .001), washout enhancement (P = .01), androgen receptor expression (P = .009), and programmed death ligand 1 expression (P = .01), demonstrating a correlation with tumor immune environment in participants with TNBC. Conclusion A radiomics score derived from pharmacokinetic parameters at pretreatment dynamic contrast-enhanced MRI exhibited good performance for predicting pCR in participants with TNBC undergoing NACI, and could potentially be used to enhance clinical decision making. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Rauch in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ramtohul T, Lepagney V, Bonneau C, et al. Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. Radiology. 2024. PMID: 39225608. doi:10.1148/radiol.240575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。